MEIP News and Press, MEI Pharma Inc. From 09/29/23

2023-09-29 13:51:22 ET More on Infinity Pharmaceuticals Infinity Pharmaceuticals receives delisting determination letter from Nasdaq Infinity Pharma cuts jobs, seeking "strategic transaction" for eganelisib Financial information for Infinity Pharmaceuticals F...

MEI Pharma, Inc. (Nasdaq: MEIP) (the “MEI” or “the Company”) today issued the following statement in response to the consent solicitation initiated by a group led by Anson Advisors Inc. and Cable Car Capital LLC. The MEI Board of Directors and management team are f...

2023-09-26 19:47:02 ET MEI Pharma, Inc. (MEIP) Q4 2023 Earnings Call Transcript September 26, 2023, 05:00 PM ET Company Participants David Walsey - SVP, Corporate Affairs David Urso - President & CEO Jay File - CFO Richard Ghalie - CMO Conference Ca...

2023-09-26 16:05:07 ET More on MEI Pharma Seeking Alpha’s Quant Rating on MEI Pharma Historical earnings data for MEI Pharma Financial information for MEI Pharma MEI Pharma FY 2023 Earnings Preview MEI Pharma large shareholders want entire boar...

-- Conference Call Today at 5:00 p.m. Eastern Time -- MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30, 2023. "Over just the next few quarters we look forw...

Nanobiotix S.A. (NBTX) is expected to report for Q2 2023 Wal-mart de Mexico S A B de C V ADR (WMMVY) is expected to report for Q2 2023 Bion Environmental Technologies Inc. (BNET) is expected to report for Q1 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-...

2023-09-25 17:35:58 ET AIR , COST , MEIP , MLKN , PRGS For Seeking Alpha's full earnings season calendar, click here . For further details see: Notable earnings after Tuesday's close

2023-09-25 17:35:22 ET More on MEI Pharma Seeking Alpha’s Quant Rating on MEI Pharma Historical earnings data for MEI Pharma Financial information for MEI Pharma MEI Pharma large shareholders want entire board removed MEI Pharma postpones speci...

2023-09-24 23:33:31 ET Summary Kyowa Kirin shares are viewed as a cheap option on the positive outcome for the atopic dermatitis drug being developed with Amgen. The company's recent track record for new drug trial success has been poor, but the partnership with Amgen provides rea...

MEI Pharma, Inc. (NASDAQ: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Company will release its 2023 fiscal year end financial results after the close of the U.S. financial markets on September 26, 2023. Company management ...